Losartan reduces the costs of diabetic end-stage renal disease: An Asian perspective

Nephrology

Volumn 10, Issue 5, 2005, Pages 520-524

  Seng, Wong Kok ^a   Hwang, Shang Jyh ^b   Han, Dong Cheol ^c   Teong, Chua Chin ^d   Chan, Juliana ^e   Burke, Thomas A ^f   Carides, George W ^f   Choi, Yon Jong ^g  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c Soonchunhyang University   (South Korea)

^d UNIVERSITY MALAYA MEDICAL CENTRE   (Malaysia)

^e CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^f MERCK RESEARCH LABORATORIES   (United States)

^g Intervet Korea Ltd   (South Korea)

Author keywords

Angiotensin II receptor antagonist; Asia; Cost; Cost effectiveness; End stage renal disease; Losartan; Type 2 diabetes mellitus

Indexed keywords

CREATININE; LOSARTAN; PLACEBO;

ADULT; AGED; ARTICLE; ASIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; CREATININE BLOOD LEVEL; DIALYSIS; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG EFFECT; FEMALE; HEALTH CARE COST; HONG KONG; HUMAN; JAPAN; KIDNEY DISEASE; KIDNEY FAILURE; KOREA; MAJOR CLINICAL STUDY; MALAYSIA; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGAPORE; TAIWAN;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DRUG COSTS; HEALTH CARE COSTS; HONG KONG; HUMANS; HYPERTENSION, RENAL; KIDNEY FAILURE, CHRONIC; KOREA; LOSARTAN; MALAYSIA; SINGAPORE; TAIWAN;

EID: 28444456302     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2005.00472.x     Document Type: Article

References (19)

1. De Vecchi AF, Dratwa M, Wiedemann ME. Healthcare systems and end-stage renal disease (ESRD) therapies - an international review: Costs and reimbursement/funding of ESRD therapies. Nephrol. Dial. Transplant. 1999; 14 (Suppl. 6): 31-41.
2. Yang WC, Hwang SJ, Chiang SS, Chen HF, Tsai ST. The impact of diabetes on economic costs in dialysis patients: Experiences in Taiwan. Diabetes Res. Clin. Pract. 2001; 54 (Suppl. 1): S47-54.
3. Lee G. End-stage renal disease in the Asian-Pacific region. Semin. Nephrol. 2003; 23: 107-14.
4. Lim TO, Lim YN (eds). Eleventh Report of the Malaysian Dialysis and Transplant Registry 2003. Kuala Lumpur: National Renal Registry, 2004.
5. Patient Registration Committee, Japanese Society for Dialysis Therapy. An overview of regular dialysis treatment in Japan (as of 31 December 2002). Ther. Apher. Dial. 2004; 8: 358-82.
6. International Diabetes Federation (eds). Diabetes Atlas. Brussels, Belgium: International Diabetes Federation, 2003.
7. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 2001; 345: 861-9.
8. Chan JC, Wat NM, So WY et al. Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: An Asian perspective from the RENAAL study. Diabetes Care 2004; 27: 874-9.
9. Hong Kong Health Authority. 2004.
10. Hwang SJ, Mau LW, Lin CY, Hwang SC. Comparisons of Service Utilization and Medical Expenses between Patients on Hemodialysis and Peritoneal Dialysis in Taiwan. TSN Annual Meeting Abstract Taipei: Taiwan Society of Nephrology, 2003 (in Chinese).
11. Li KT, Chow KM. The cost barrier to peritoneal dialysis in the developing world: An Asian perspective. Perit. Dial. Int. 2001; 21 (Suppl. 3): S307-13.
12. Kim SY, Jin DC, Bang BK. Current status of dialytic therapy in Korea. Nephrology 2003; 8 (Suppl. 2): S2-9.
13. Hwang SJ, Yang WC and the Dialysis Surveillance Committee. 1999 National Dialysis Surveillance in Taiwan. Acta Nephrologica 2004; 14: 139-228.
14. Lui SF, Ho YW, Chau KF, Leung CB, Choy BY. Hong Kong renal registry 1995-1999. Hong Kong J. Nephrol. 1999; 1: 53-60.
15. Carides GW, Heyse JF, Iglewicz B. A regression-based method for estimating mean treatment cost in the presence of right-censoring. Biostatistics 2000; 1: 299-313.
16. Efron BT. An Introduction to the Bootstrap. New York: Chapman & Hall, 1993.
17. Herman WH, Shahinfar S, Carides GW et al. Losartan reduces the costs associated with diabetic end-stage renal disease: The RENAAL study economic evaluation. Diabetes Care 2003; 26: 683-7.
18. Wong KS, Kurokawa K, Chan JC et al. Losartan reduces the burden and cost of ESRD: Public health implications from the RENAAL study for the western Pacific region (WPR). Congress of the ASEAN Federation of Endocrine Societies (AFES) and Oceania Thyroid Association (OTA) Congress. 2003.
19. Ramirez SP, Hsu SI, Nandakumar M, Friedman EA, Durai TT, Owen WF Jr. Funding ESRD care through charity: The paradigm of the National Kidney Foundation of Singapore. Semin. Nephrol. 2001; 21: 411-18.